Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

BACKGROUND Approximately 50% of patients with schizophrenia or schizoaffective disorder attempt suicide, and approximately 10% die of suicide. Study results suggest that clozapine therapy significantly reduces suicidal behavior in these patients. METHODS A multicenter, randomized, international, 2-year study comparing the risk for suicidal behavior in patients treated with clozapine vs olanzapine was conducted in 980 patients with schizophrenia or schizoaffective disorder, 26.8% of whom were refractory to previous treatment, who were considered at high risk for suicide because of previous suicide attempts or current suicidal ideation. To equalize clinical contact across treatments, all patients were seen weekly for 6 months and then biweekly for 18 months. Subsequent to randomization, unmasked clinicians at each site could make any interventions necessary to prevent the occurrence of suicide attempts. Suicidal behavior was assessed at each visit. Primary end points included suicide attempts (including those that led to death), hospitalizations to prevent suicide, and a rating of "much worsening of suicidality" from baseline. Masked raters, including an independent suicide monitoring board, determined when end point criteria were achieved. RESULTS Suicidal behavior was significantly less in patients treated with clozapine vs olanzapine (hazard ratio, 0.76; 95% confidence interval, 0.58-0.97; P =.03). Fewer clozapine-treated patients attempted suicide (34 vs 55; P =.03), required hospitalizations (82 vs 107; P =.05) or rescue interventions (118 vs 155; P =.01) to prevent suicide, or required concomitant treatment with antidepressants (221 vs 258; P =.01) or anxiolytics or soporifics (301 vs 331; P =.03). Overall, few of these high-risk patients died of suicide during the study (5 clozapine vs 3 olanzapine-treated patients; P =.73). CONCLUSIONS Clozapine therapy demonstrated superiority to olanzapine therapy in preventing suicide attempts in patients with schizophrenia and schizoaffective disorder at high risk for suicide. Use of clozapine in this population should lead to a significant reduction in suicidal behavior.

Alan I Green | Steven Potkin | Herbert Y Meltzer | Ravi Anand | Larry Alphs | John Kane | S. Potkin | R. Emsley | R. Kerwin | I. Bitter | J. Daléry | A. Mortimer | A. Green | I. Glick | G. Simpson | P. Llorca | J. Krasuski | D. Robinson | H. Meltzer | A. Altamura | P. Delgado | C. Eisdorfer | F. Rouillon | J. Lindenmayer | L. Alphs | R. Josiassen | R. Balon | M. Jakovljevič | D. Zimbroff | D. Sack | Tom Fahy | G. Chouinard | B. Carpiniello | M. Rapaport | M. Bourgeois | J. Kane | L. Dell’Osso | R. Anand | V. Larach | A. Bertoldi | M. Z. Islam | R. Krishnan | G. Grossberg | A Carlo Altamura | D. Casey | I. Paclt | Guy Chouinard | Alberto Bertoldi | Marc Bourgeois | M Zahur Islam | Ranga Krishnan | J P Lindenmayer | L. Mód | M. Lesem | J. Chou | L. Pestreich | C. Robotti | Siemion Altman | D. Gundersen | Stephen Martin | T. Posever | Shôn Lewis | N. Iqbal | V. Folnegovic | J. Peters | M. Knesevich | M. Noursalehi | F. Khidichian | A. Giannelli | Vinod Kumar | M. Plopper | G. Hsu | Naveed Iqbal | G. Cassano | Mark Hyman Rapaport | Robert Kerwin | Richard Balon | F. Young | Ira D. Glick | Michael D. Lesem | Jörg-Peter Pahl | Liliana Dell'Osso | O. Tomori | Richard C. Josiassen | P. Gargoloff | Jean-Pierre Lindenmayer | Saide Altinsan | Siemion Altman | Likiana Avigo | Vanda Benešová | Luis Bengochea | István Bitter | Elisabeth Bokowska | Bernardo Carpiniello | James C.-Y. Chou | Libor Chvila | Jean Dalery | Pedro L. Delgado | Dawn Eng | Tom A. Fahy | Vera Folnegovic | S. Frangou | Pedro Gargoloff | Alberto Giannelli | Richard I. Greenberg | George T. Grossberg | Doris Gundersen | Hannale Heila | George Hsu | Akos Kassaifarkas | Frederic Khidichian | Jack S. Krasuski | Veronica W. Larach | Shôn Lewis | Pierre-Michel Llorca | H. Edward Logue | Muriel Maurel-Raymondet | Laszlo Mod | Eva Morik | Carlos Morra | Ann M. Mortimer | Mojtaba Noursalehi | Gyorgy Ostorharics-Horvath | Ivo Paclt | Jörg Pahl | Linda Pestreich | Rosario Pioli | Michael G. Plopper | Thomas Posever | Carlo Andrea Robotti | Harry Rohme | Frédéric Rouillon | Isaac Sakinsofsky | Phillip Seibel | George M. Simpson | Nancy Temkin | Oladapo Tomori | Santha Vaidain | Zdeòka Vyhnándová | Daniel L. Zimbroff | M. Zimmerman | Saide Altinsan | Likiana Avigo | Vanda Benesová | Luis Bengochea | Elisabeth Bokowska | L. Chvila | D. Eng | Hannale Heila | Akos Kassaifarkas | Vinod Kumar | H. Logue | Muriel Maurel-Raymondet | Eva Morik | C. Morra | G. Ostorharics-Horvath | Rosario Pioli | Michael G. Plopper | Harry Rohme | Isaac Sakinsofsky | Phillip Seibel | N. Temkin | Santha Vaidain | Zdeòka Vyhnándová | M. A. Knesevich | Michael G. Plopper

[1]  D. LeBihan,et al.  Functional anatomy of cognitive development , 2000, Neurology.

[2]  F. Gawin The scientific exegesis of desire: neuroimaging crack craving. , 2001, Archives of general psychiatry.

[3]  P. Allison Survival analysis using the SAS system : a practical guide , 1995 .

[4]  Godfrey D. Pearlson,et al.  Structural differences in the cerebral cortex of healthy female and male subjects: a magnetic resonance imaging study , 1995, Psychiatry Research: Neuroimaging.

[5]  C. Ehlers,et al.  Evaluation of EEG alpha activity in sons of alcoholics. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[6]  M. Schuckit,et al.  The relationships of a family history of alcohol dependence, a low level of response to alcohol and six domains of life functioning to the development of alcohol use disorders. , 2000, Journal of studies on alcohol.

[7]  S. Siris Suicide and schizophrenia , 2001, Journal of psychopharmacology.

[8]  Patricia Cohen,et al.  Television Viewing and Aggressive Behavior During Adolescence and Adulthood , 2002, Science.

[9]  Jonathan D. Cohen,et al.  Improved Assessment of Significant Activation in Functional Magnetic Resonance Imaging (fMRI): Use of a Cluster‐Size Threshold , 1995, Magnetic resonance in medicine.

[10]  L. J. Wei,et al.  Regression analysis of multivariate incomplete failure time data by modeling marginal distributions , 1989 .

[11]  I. Gottesman,et al.  Schizophrenics kill themselves too: a review of risk factors for suicide. , 1990, Schizophrenia bulletin.

[12]  A L Malizia,et al.  Changes in regional cerebral blood flow elicited by craving memories in abstinent opiate-dependent subjects. , 2001, The American journal of psychiatry.

[13]  John G Sonnenberg,et al.  Reduction of Suicidality in Patients with Schizophrenia Receiving Clozapine , 2002 .

[14]  E. C. Harris,et al.  Suicide as an outcome for mental disorders , 1997, British Journal of Psychiatry.

[15]  William D S Killgore,et al.  Sex-specific developmental changes in amygdala responses to affective faces , 2001, Neuroreport.

[16]  A. Nyman,et al.  Patterns of self‐destructive behaviour in schizophrenia , 1986, Acta psychiatrica Scandinavica.

[17]  J. Polich,et al.  P300 latency after ethanol ingestion in sons of alcoholics and in controls , 1988, Biological Psychiatry.

[18]  H. Meltzer,et al.  Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. , 1995, The American journal of psychiatry.

[19]  G. Tollefson,et al.  Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. , 1997 .

[20]  W. Brown,et al.  Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database. , 2001, The American journal of psychiatry.

[21]  L. Cohen,et al.  Suicide and schizophrenia: data from a prospective community treatment study. , 1990, The American journal of psychiatry.

[22]  A. Perényi,et al.  Suicide in schizophrenia. , 2005, Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology.

[23]  M. Tsuang,et al.  The Iowa 500: suicide in mania , depression, and schizophrenia. , 1975, The American journal of psychiatry.

[24]  D G Altman,et al.  Confidence intervals for the number needed to treat , 1998, BMJ.

[25]  D. Collet Modelling Survival Data in Medical Research , 2004 .

[26]  D. Kennedy,et al.  The human brain age 7-11 years: a volumetric analysis based on magnetic resonance images. , 1996, Cerebral cortex.

[27]  M. Slater,et al.  Adolescent Counterarguing of TV Beer Advertisements: Evidence for Effectiveness of Alcohol Education and Critical Viewing Discussions , 1996, Journal of drug education.

[28]  B. Singh,et al.  Suicide: the public health crisis of our time. , 1998, Australian and New Zealand journal of medicine.

[29]  J C Gore,et al.  Functional magnetic resonance imaging of cocaine craving. , 2001, The American journal of psychiatry.

[30]  W. Reid,et al.  Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. , 1998, Psychiatric services.

[31]  H. Kraemer,et al.  Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. , 1999, The American journal of psychiatry.

[32]  I. Gottesman,et al.  Schizophrenia--a high-risk factor for suicide: clues to risk reduction. , 1992, Suicide & life-threatening behavior.

[33]  G. Boynton,et al.  Global effects of feature-based attention in human visual cortex , 2002, Nature Neuroscience.

[34]  K. Zilles,et al.  Subcortical correlates of craving in recently abstinent alcoholic patients. , 2001, The American journal of psychiatry.

[35]  Douglas C. Noll,et al.  A Developmental Functional MRI Study of Spatial Working Memory , 1999, NeuroImage.

[36]  M. Sajatovic,et al.  An assessment of clinical practice of clozapine therapy for veterans. , 2000, Psychiatric services.

[37]  J. Polich,et al.  Auditory P3a deficits in male subjects at high risk for alcoholism , 2001, Biological Psychiatry.

[38]  H. Meltzer Treatment of Suicidality in Schizophrenia , 2001, Annals of the New York Academy of Sciences.

[39]  R. Axelsson,et al.  Factors predicting suicide in psychotic patients , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[40]  Larry Alphs,et al.  The InterSePT scale for suicidal thinking reliability and validity , 2003, Schizophrenia Research.

[41]  H. Meltzer,et al.  Suicide in Schizophrenia: The Effect of Clozapine , 1995 .

[42]  G. Cassano,et al.  Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. , 2000, The Journal of clinical psychiatry.

[43]  R. Rosenheck,et al.  Impact of clozapine on completed suicide. , 2001, The American journal of psychiatry.

[44]  J. Sweeney,et al.  Suicidal behavior in patients with schizophrenia and other psychotic disorders. , 1999, The American journal of psychiatry.

[45]  Gina E. Agostinelli,et al.  Alcohol counter-advertising and the media. A review of recent research. , 2002 .

[46]  K. Rothman,et al.  Mortality in current and former users of clozapine , 1996, Schizophrenia Research.

[47]  R. Elliott,et al.  Ventromedial prefrontal cortex mediates guessing , 1999, Neuropsychologia.

[48]  R. Kerwin,et al.  Active monitoring of 12760 clozapine recipients in the UK and Ireland , 1999, British Journal of Psychiatry.